Copper and trace elements in biliary tract cancer
Part of Cancer, Digestive system clinical trials.
This study looks at levels of copper and other minerals in the blood of people with biliary tract cancer (cancer of the bile ducts or gallbladder). If you have not had treatment yet, this trial may help doctors understand how these elements relate to your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been diagnosed with biliary tract cancer (cancer of the bile ducts or gallbladder) through a biopsy or cell test.
- You must not have received any chemotherapy or radiation for advanced or spread cancer before starting this study.
- You must be in good enough health to carry out daily activities (like walking and self-care) — your doctor will rate this.
- You must have had a CT scan of your chest and belly within the last 4 weeks before starting treatment.
- You must not have a serious autoimmune disease or be taking medications that weaken your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to track how well bile duct cancer responds to treatment and to predict outcomes. It may help doctors make better decisions about surgery and other therapies.
This study looks at lab markers (including genetic tests) to predict how people with bile duct cancer respond to treatment. Your answers and samples may help doctors personalize care for bile duct cancer in the future.
This study analyzes tumor tissue samples from patients with biliary tract cancer (a rare cancer of the bile ducts or gallbladder) to identify genetic and protein markers that may help doctors better understand and treat the disease. Your stored tissue sample and medical records would be used to find patterns that could improve future treatment options.
This trial tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) for biliary tract cancer that can be removed by surgery. The goal is to prevent cancer from coming back after surgery.
This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.
This study tracks how bile duct and liver cancers change during treatment, to help doctors find the best therapies for patients. It is for people who are newly diagnosed or starting a new treatment.
Hear when a new Trace Element Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.